GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01984086
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Phase 3
Completed
- Conditions
- Neisseria MeningitidisHaemophilus Influenzae Type b
- Interventions
- Biological: Hib-MenCY-TT (MenHibrix®)Biological: Pediarix®Biological: Rotarix®Biological: Prevnar 13®Biological: PedvaxHIB®Biological: Havrix®
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT01978093
- Locations
- 🇺🇸
GSK Investigational Site, Syracuse, Utah, United States
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FSCDrug: Placebo
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 665
- Registration Number
- NCT01978145
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhzhia, Ukraine
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Phase 2
Terminated
- Conditions
- Melanoma and Brain Metastases
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT01978236
- Locations
- 🇦🇺
GSK Investigational Site, North Sydney, New South Wales, Australia
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
Phase 1
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: drug-drug interaction
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT01978327
- Locations
- 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: FSCDrug: Placebo
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 124
- Registration Number
- NCT01978119
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhzhia, Ukraine
Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis
Withdrawn
- Conditions
- Infections, Rotavirus
- Interventions
- Procedure: Stool sample collection
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01978223
Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT01978301
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 252
- Registration Number
- NCT01977573
- Locations
- 🇬🇧
GSK Investigational Site, Oxford, United Kingdom
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 216
- Registration Number
- NCT01977482
- Locations
- 🇬🇧
GSK Investigational Site, Oxford, United Kingdom